sAfety PerfoRmance chitOsan osteOarthritis ViscosupplEmentation

NCT03679208 | Unknown DMC

• 1 other identifier: KIO014-APROOVE
• Study Type: interventional
• Target: 100
• Locations: 0 countries
• Sites: N/A

Brief Summary

KIO014 is an innovative chitosan-based biomaterial intended for synovial fluid viscosupplementation indicated for the symptomatic treatment of knee osteoarthritis (OA). The study KIO014-APROOVE is aimed to evaluate the safety and performance of KIO014 in patients with symptomatic knee OA. A total of 100 patients will be enrolled. The study is divided in two stages. The Stage 1 cohort is the safety cohort where 10 patients will be enrolled. Stage 1 patients receiving two injections of KIO014 at day 0 and at month 3, and will be followed for 12 months post initial injection. The Stage 2 cohort is the performance cohort for 90 patients, and this stage will be randomized controlled and single-blind for the patient. In stage 2, 60 patients will receive an intra-articular injection of KIO014 (test group) and 30 patients will receive an intra-articular injection of Durolane® (control group). Patients will be followed for 6 months.

Conditions

Knee Osteoarthritis

Outcome Measures

Primary Outcomes (2)

• Safety using 4-point numerical rating scale for local effects

  At each visit, the treatment knee is assessed for the occurrence of local effects (joint pain, effusion or swelling) using a 4-point numerical rating scale (NRS) graded 0-3 (none, mild, moderate or severe).

  All time points for up to 12 months

• Change in pain at 3 months versus pre-injection baseline using the 5-graded Likert self-administered WOMAC pain questionnaire (Stage 2 cohort only)

  The WOMAC (Western Ontario and McMaster Universities Osteoarthritis Index) is a self-administered questionnaire designed to assess pain, stiffness, and physical function through a series of 24 questions divided into 3 subscales. The WOMAC pain score consists of 5 questions. Each question is graded 0-4 on the 5-graded Likert scale (none, mild, moderate, severe or extreme) relating to how much pain the subject has experienced during the last 48 hours. The mean score is reported.

  3 months

Secondary Outcomes (5)

• Changes from baseline in total score, pain, stiffness, and physical functioning subscales of the treatment knee as measured using the 5-graded Likert WOMAC at the different time points over 6 months.

  6 months

• Changes from baseline in subject's pain using an 11-point Numerical Rating Scale (NRS) at the different time points over 6 months.

  6 months

• Changes from baseline in subject's global assessment using an 11-point Numerical Rating Scale (NRS) at the different time points over 6 months.

  6 months

• Response to treatment according to Osteoarthritis Research Society International (OARSI) Standing Committee for Clinical Trials Response Criteria Initiative and the Outcome Measures in Rheumatology (OMERACT) at the different time points over 6 months.

  6 months

• Treatment responders with >40% improvement in pre-injection pain (WOMAC Likert) at the different time points over 6 months.

  6 months

Study Arms (3)

Stage 1 Safety cohort

EXPERIMENTAL

Two injections of the investigational device (KIO014) at 3-month interval in 10 patients and 12-month follow-up to establish long-term safety as primary endpoint.

Device: Investigational device coded KIO014

Stage 2 Performance (test group)

EXPERIMENTAL

One injection of the investigational device (KIO014) in 60 patients to evaluate the reduction in pain at 3 months as primary endpoint. Additional follow-up at 6 months.

Device: Investigational device coded KIO014

Stage 2 Performance (control group)

ACTIVE COMPARATOR

One injection of the control device (Durolane(r)) in 30 patients to evaluate the reduction in pain at 3 months as control endpoint. Additional follow-up at 6 months.

Device: Durolane(r) as control device

Interventions

Investigational device coded KIO014 DEVICE

Innovative chitosan-based biomaterial intended for intraarticular injection.

Stage 1 Safety cohort; Stage 2 Performance (test group)

Durolane(r) as control device DEVICE

Crosslinked hyaluronic acid-based biomaterial intended for intraarticular injection.

Stage 2 Performance (control group)

Eligibility Criteria

• Age: 40 Years - 85 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Male or female with age ≥ 40 years and ≤ 85 years except in Stage 1 cohort where age is limited to ≤ 70 years.
• Body mass index (BMI) ≤ 35 kg/m².
• Uni- or bilateral femorotibial knee OA associated or not with femoropatellar knee OA.
• Primary knee osteoarthritis responding to the clinical and radiological criteria of the American College of Rheumatology (ACR)
• Radiological Kellgren and Lawrence (K\&L) grade II to III from a standing knee radiograph taken less than 6 months previously.
• Symptomatic pain at least 6 months in the treatment knee not or poorly responding to first line non-opioid analgesics and non-steroidal anti-inflammatory drug in oral uptake.
• Pain criteria assessed prior to injection at visit 1 after mandatory 48-hour wash-out:
• Treatment knee: 7-17 points of the 5-graded Likert WOMAC pain score and at least 2 points on the WOMAC pain subscore A1 in the most affected knee.
• Non-treatment knee: not more than 6 points of the 5-graded Likert WOMAC pain score in the contralateral knee.
• Fully ambulatory patient for functional evaluation
• Willing NOT to take any pain medication for 48 hours prior to study visit.
• For female NOT surgically sterile (tubal ligation or hysterectomy) or NOT postmenopausal for at least one year, must have an effective contraception (pill, patch, ring, diaphragm, implant and intrauterine device).
• Able to understand and follow the instructions of the study.
• Having signed a written informed consent.

You may not qualify if:

• Related to the OA pathology and related symptoms:
• Radiological K\&L grade 0, I or IV from a standing knee radiograph taken less than 6 months previously.
• Exclusively patellofemoral osteoarthritis where the symptoms, including pain, are principally of patellofemoral origin (Patellar syndrome).
• Chondromatosis or villonodular synovitis of the knee.
• Clinically-apparent knee effusion, inflammation or flare-up of the knee or abnormal synovial fluid macroscopy or volume upon arthrocentesis on the day of injection.
• Significant clinically-assessed or radiographic varus or valgus deformation of the selected knee at the judgment of the investigator.
• Inflammatory disease.
• Pathologies interfering with the evaluation of OA pain for the knee to be treated.
• Related to treatments:
• Contraindications: hypersensitivity or allergy to the product components of KIO014, including chitosan, sorbitol and/or other mushroom-derived products, or to hyaluronic acid-based products.
• Corticosteroids or Plasma Rich Platelet (PRP) or cell-based therapy injection in the treatment knee in the last 3 months before injection.
• Hyaluronic acid injection in the treatment knee in the last 6 months before injection.
• Arthroscopy and surgery in the treatment knee in the last 6 months before injection.
• Oral corticotherapy ≥5 mg/day (in prednisone equivalent) in the last 3 months before injection.
• Change in the dosage regimen of symptomatic slow-acting drugs (SYSAD) or dietary supplement in the last 3 months before injection.

Sponsors & Collaborators

• Kiomed Pharma: lead

MeSH Terms

Conditions

Osteoarthritis, Knee

Condition Hierarchy (Ancestors)

Osteoarthritis; Arthritis; Joint Diseases; Musculoskeletal Diseases; Rheumatic Diseases

Study Design

• Study Type: interventional
• Phase: not applicable
• Allocation: RANDOMIZED
• Masking: SINGLE
• Who Masked: PARTICIPANT
• Purpose: TREATMENT
• Intervention Model: PARALLEL
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: July 9, 2018
• First Posted: September 20, 2018
• Study Start: October 15, 2018
• Primary Completion: May 15, 2019
• Study Completion: December 15, 2019
• Last Updated: September 21, 2018

Record last verified: 2018-09